Search Results
You are looking at 1 - 1 of 1 items for
- Author: Renata Lopes Araujo x
- Refine by access: Open Access content only x
Search for other papers by Alvaro Souto Padron in
Google Scholar
PubMed
Laboratório de Fisiologia Endócrina Doris Rosenthal, Laboratório de Biologia do Exercício, Instituto de Biofísica Carlos Chagas Filho and Instituto de Pesquisa Translacional em Saúde e Ambiente na Região Amazônica (INPeTAM), CCS-Bloco G- Cidade Universitria, Ilha do Fundo, Rio de Janeiro 21949-900, Brazil
Search for other papers by Ruy Andrade Louzada Neto in
Google Scholar
PubMed
Search for other papers by Thiago Urgal Pantaleão in
Google Scholar
PubMed
Search for other papers by Maria Carolina de Souza dos Santos in
Google Scholar
PubMed
Search for other papers by Renata Lopes Araujo in
Google Scholar
PubMed
Search for other papers by Bruno Moulin de Andrade in
Google Scholar
PubMed
Search for other papers by Monique da Silva Leandro in
Google Scholar
PubMed
Search for other papers by João Pedro Saar Werneck de Castro in
Google Scholar
PubMed
Search for other papers by Andrea Claudia Freitas Ferreira in
Google Scholar
PubMed
Search for other papers by Denise Pires de Carvalho in
Google Scholar
PubMed
In general, 3,5-diiodothyronine (3,5-T2) increases the resting metabolic rate and oxygen consumption, exerting short-term beneficial metabolic effects on rats subjected to a high-fat diet. Our aim was to evaluate the effects of chronic 3,5-T2 administration on the hypothalamus–pituitary–thyroid axis, body mass gain, adipose tissue mass, and body oxygen consumption in Wistar rats from 3 to 6 months of age. The rats were treated daily with 3,5-T2 (25, 50, or 75 μg/100 g body weight, s.c.) for 90 days between the ages of 3 and 6 months. The administration of 3,5-T2 suppressed thyroid function, reducing not only thyroid iodide uptake but also thyroperoxidase, NADPH oxidase 4 (NOX4), and thyroid type 1 iodothyronine deiodinase (D1 (DIO1)) activities and expression levels, whereas the expression of the TSH receptor and dual oxidase (DUOX) were increased. Serum TSH, 3,3′,5-triiodothyronine, and thyroxine were reduced in a 3,5-T2 dose-dependent manner, whereas oxygen consumption increased in these animals, indicating the direct action of 3,5-T2 on this physiological variable. Type 2 deiodinase activity increased in both the hypothalamus and the pituitary, and D1 activities in the liver and kidney were also increased in groups treated with 3,5-T2. Moreover, after 3 months of 3,5-T2 administration, body mass and retroperitoneal fat pad mass were significantly reduced, whereas the heart rate and mass were unchanged. Thus, 3,5-T2 acts as a direct stimulator of energy expenditure and reduces body mass gain; however, TSH suppression may develop secondary to 3,5-T2 administration.